The authors identified 58 patients who underwent RC at our institution after prior PC for UC from 1980‒2010. These patients were then matched 1:3 to 174 patients undergoing primary RC based on age, pathologic T and N stage, and decade of surgery. Perioperative outcomes were compared between groups using descriptive statistics. Cancer-specific (CSS) and overall survival (OS) were evaluated using the Kaplan-Meier method and Cox proportional hazards regression.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
In summary, patients who undergo RC for recurrent UC after prior PC have similar perioperative morbidity to stage-matched patients undergoing primary RC; however, such patients may be at a higher risk of subsequently dying from UC. These data may be used in counselling patients considering PC as initial treatment for invasive UC, as well as for consideration of adjuvant therapy after RC following PC.
Presented By: Ross J. Mason, MD, Mayo Clinic, Rochester, MN, United States
Written By: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre Twitter: @GoldbergHanan at the 72nd Canadian Urological Association Annual Meeting - June 24 - 27, 2017 - Toronto, Ontario, Canada